Clearside Biomedical (STU:CLM0) Cyclically Adjusted Book per Share: €11.36 (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:CLM0 Clearside Biomedical Inc STU:CLM0
49 GF Score
Price €4.35
GF Value €110.06
! 7 Warning Signs
View Full Analysis

What is Clearside Biomedical Cyclically Adjusted Book per Share?

Clearside Biomedical STU:CLM0 49 Cyclically Adjusted Book per Share is €11.36 as of Sep. 2025. GuruFocus rates STU:CLM0 with a GF Score™ of 49/100 and a GF Value™ of €110.06. The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Clearside Biomedical's adjusted book value per share for the three months ended in Sep. 2025 was €-8.782. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €11.36 for the trailing ten years ended in Sep. 2025.

During the past 12 months, Clearside Biomedical's average Cyclically Adjusted Book Growth Rate was -3.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-26), Clearside Biomedical's current stock price is €4.35. Clearside Biomedical's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2025 was €11.36. Clearside Biomedical's Cyclically Adjusted PB Ratio of today is 0.38.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Clearside Biomedical was 2.02. The lowest was 0.01. And the median was 1.05.


Clearside Biomedical  (STU:CLM0) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Clearside Biomedical's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=4.35/11.36
=0.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Clearside Biomedical was 2.02. The lowest was 0.01. And the median was 1.05.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Clearside Biomedical Cyclically Adjusted Book per Share Related Terms


Clearside Biomedical Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Clearside Biomedical's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clearside Biomedical Cyclically Adjusted Book per Share Chart

Clearside Biomedical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 10.43

Clearside Biomedical Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.15 10.43 9.73 8.47 11.36

STU:CLM0 vs LYRA, EVFM, ATXI: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Clearside Biomedical's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clearside Biomedical Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clearside Biomedical's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Clearside Biomedical's Cyclically Adjusted PB Ratio falls into.


STU:CLM0
49GF Score
Clearside Biomedical Inc STU:CLM0
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clearside Biomedical Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Clearside Biomedical's adjusted Book Value per Share data for the three months ended in Sep. 2025 was:

Adj_Book= Book Value per Share /CPI of Sep. 2025 (Change)*Current CPI (Sep. 2025)
=-8.782/324.8000*324.8000
=-8.782

Current CPI (Sep. 2025) = 324.8000.

Clearside Biomedical Quarterly Data

Book Value per Share CPI Adj_Book
201512 -31.074 236.525 -42.671
201603 4.532 238.132 6.181
201606 31.276 241.018 42.148
201609 30.527 241.428 41.069
201612 41.473 241.432 55.794
201703 37.224 243.801 49.591
201706 28.626 244.955 37.957
201709 18.327 246.819 24.117
201712 10.708 246.524 14.108
201803 32.718 249.554 42.583
201806 26.731 251.989 34.455
201809 17.694 252.439 22.766
201812 9.697 251.233 12.537
201903 5.808 254.202 7.421
201906 4.538 256.143 5.754
201909 3.230 256.759 4.086
201912 3.391 256.974 4.286
202003 3.159 258.115 3.975
202006 2.098 257.797 2.643
202009 2.145 260.280 2.677
202012 2.084 260.474 2.599
202103 3.716 264.877 4.557
202106 4.075 271.696 4.871
202109 3.817 274.310 4.520
202112 8.440 278.802 9.832
202203 7.179 287.504 8.110
202206 5.956 296.311 6.529
202209 4.668 296.808 5.108
202212 2.477 296.797 2.711
202303 0.616 301.836 0.663
202306 -1.116 305.109 -1.188
202309 -2.908 307.789 -3.069
202312 -3.482 306.746 -3.687
202403 -4.027 312.332 -4.188
202406 -5.274 314.175 -5.452
202409 -6.290 315.301 -6.479
202412 -7.269 315.605 -7.481
202503 -8.243 319.799 -8.372
202506 -8.074 322.561 -8.130
202509 -8.782 324.800 -8.782

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €11.36 mean?
Clearside Biomedical (STU:CLM0) has a Cyclically Adjusted Book per Share of €11.36 as of Sep. 2025. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Clearside Biomedical and its competitors.
Is Clearside Biomedical's Cyclically Adjusted Book per Share too high?
Clearside Biomedical's current Cyclically Adjusted Book per Share is €11.36. Overall, Clearside Biomedical has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Clearside Biomedical's Cyclically Adjusted Book per Share compare to LYRA and EVFM?
Clearside Biomedical's Cyclically Adjusted Book per Share of €11.36 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Clearside Biomedical and its competitors. Clearside Biomedical's current Cyclically Adjusted Book per Share is €11.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clearside Biomedical stock overvalued right now?
Clearside Biomedical (STU:CLM0) has a current Cyclically Adjusted Book per Share of €11.36. The stock's GF Value™ is €110.06, compared to a current price of €4.35 — trading 96% below its estimated fair value. The current Cyclically Adjusted Book per Share is €11.36. Clearside Biomedical's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Clearside Biomedical (STU:CLM0), the current Cyclically Adjusted Book per Share is €11.36 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Clearside Biomedical (STU:CLM0) Overvalued in 2026?

Based on GuruFocus' analysis, Clearside Biomedical stock appears to be undervalued. The current stock price of €4.35 is trading 96% below its estimated GF Value™ of €110.06.

Key valuation signals for STU:CLM0:

  • Cyclically Adjusted Book per Share: €11.36
  • GF Value™: €110.06 vs. price of €4.35 (96% below fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the STU:CLM0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Clearside Biomedical Business Description

Other Exchanges CLSDQ:USA
Address 900 North Point Parkway, Suite 200, Alpharetta, GA, USA, 30005
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
49GF Score

Get the complete analysis for STU:CLM0

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.35
Price
€110.06
GF Value